Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

BREAKING: NHS boss Simon Stevens quits

The government says Sir Simon Stevens will be stepping down as chief executive of NHS England from July and become a peer.

A government press release on Thursday (April 29) said: “The Queen has been pleased to confer a peerage of the United Kingdom for life on Sir Simon Stevens, upon him stepping down as chief executive of NHS England.”


In a statement from NHS England, Sir Simon said: “Joining the health service in my early 20s was one of the best decisions I’ve ever made, followed three decades later by the privilege of leading the NHS through some of the toughest challenges in its history.

Sir Simon became chief executive of NHS England in 2014, having first joined the NHS in 1988 through its graduate management programme.

He added: “The people of this country have rightly recognised the extraordinary service of NHS staff through this terrible pandemic, as well as the success of our Covid vaccination deployment.

“As the pandemic recedes in this country, the NHS’s track record in advancing medical progress in a way that works for everyone rightly continues to inspire young people to join one of the greatest causes – health and high quality care for all, now and for future generations.”

In a varied career before becoming the boss of NHS England, Sir Simon worked in frontline NHS roles and in international health care, in both the public and private sectors, and at 10 Downing Street and the Department of Health.

He was knighted in 2020 for services to Health & the NHS.

Prime minister Boris Johnson said Sir Simon had "led the NHS with great distinction".

Commenting on the news, Labour leader Keir Starmer said the "NHS Covid-19 vaccination programme under his leadership has shown the NHS at its best.”

Jonathan Ashworth MP, labour’s shadow health secretary called Sir Simon "an outstanding leader for the NHS since 2014, championing both staff and patients alike".

More For You

Astrazeneca Office Building  Outlook

British Medical Journal has found data discrepancy during the crucial clinical trials of AstraZeneca's heart drug ticagrelor.

iStock

Top medics question trials of AstraZeneca's anti-clotting pill

The effectiveness of anti-clotting pill ticagrelor is now under a cloud, with some experts claiming that AstraZeneca misreported data when the trials were conducted more than a decade ago.

Sold as Brilinta, the pill was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack, and the generic versions of the drug are scheduled for this year.

Keep ReadingShow less
Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

iStock

Pensions Ombudsman probing Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

According to the Pharmacists' Defence Association (PDA), the ombudsman has decided to take a ‘lead case’ approach, as several members have been affected by the issue.

Keep ReadingShow less
23andMe

More than 150,000 UK residents had their personal information taken by hackers during a data breach in 2023.

iStock

UK watchdog fines 23andMe £2.31m for data breach

Genetic testing firm 23andMe has been fined £2.31 million by a UK watchdog over a 2023 data breach, when the personal information of seven million people across the world was stolen.

The Information Commissioner's Office (ICO) said the California-based company, which later filed for bankruptcy, failed to put adequate measures in place to secure sensitive user data.

Keep ReadingShow less
Henry Gregg, new Chief Executive of the National Pharmacy Association.
Henry Gregg
Henry Gregg

Community pharmacy voices need to be ‘heard really loud’, new NPA chief tells Pharmacy Business

Henry Gregg, the new chief executive of the National Pharmacy Association (NPA), believes community pharmacies have a right to have insight into discussions relating to the pharmacy funding contract.

Currently, Community Pharmacy England (CPE) solely negotiates the elements of the Community Pharmacy Contractual Framework (CPCF) with the Department of Health and Social Care (DHSC) and NHS England.

Keep ReadingShow less
Patient care

The NHS said the benefits were "too small to justify the additional cost"

NHS rejects Alzheimer's drugs shown to delay early-stage of disease

Two new treatments for Alzheimer's disease will not be offered on the NHS due to high costs and "too small" benefits.

Donanemab and Lecanemab have been hailed as breakthrough treatments for slowing down the symptoms of early-stage Alzheimer's, the most common type of dementia.

Keep ReadingShow less